1/24/14 update
Jan 2014
Nov 2013
Description
Relypsa, Inc. is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Company has completed its two-part pivotal Phase III trial of its product candidate, patiromer, for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. The Company has designed patiromer to efficiently bind and remove potassium from the body, thereby treating hyperkalemia. The Company has conducted a clinical development program, in which daily administration of patiromer has been observed by the Company to lower, and maintain control of, serum potassium levels in hyperkalemic subjects with an acceptable safety and tolerability profile.
Address
700 Saginaw Drive
REDWOOD CITY, CA 94063
United States
REDWOOD CITY, CA 94063
United States
Key stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -314.24% | -92.43% |
| Return on average equity | - | - |
| Employees | 69 |
No comments:
Post a Comment